XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.1
10. Segment Information Segment Reporting
 3 Months Ended
Mar. 31, 2023
Segment Reporting [Abstract]  
Segment Reporting Disclosure [Text Block] SEGMENT INFORMATION
Information regarding operating profit for the three months ended March 31, 2023 and 2022 is as follows (in millions):
Life
Science		Clinical
Diagnostics		Other
Operations
Net Sales2023$323.6 $352.1 $1.1 
2022$347.2 $351.8 $1.1 
Operating Profit2023$35.7 $26.3 $(0.1)
2022$89.6 $57.1 $(0.3)



Segment results are presented in the same manner as we manage our business internally to make operating decisions and assess performance. Our chief operating decision maker ("CODM") views all operating expenses and corporate
overhead as directly supporting the strategies of our segments and these costs are fully allocated to our reportable segments.

The following reconciles total segment profit to consolidated income (loss) before income taxes (in millions):

Three Months Ended
March 31,
 20232022
Operating profit $61.9 $146.4 
Interest expense(12.3)(4.0)
Foreign currency exchange gains (losses), net2.3 2.1 
Change in fair market value of equity securities(17.5)(4,545.1)
Other income (expense), net50.4 32.6 
Consolidated income (loss) before income taxes$84.8 $(4,368.0)